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Background: An increase in mitochondrial DNA (mtDNA) content and mitochondrial biogenesis associated with
the activation of PGC-1α signalling pathway was previously reported in type I endometrial cancer. The aim of this
study has been to evaluate if mtDNA content and the citrate synthase (CS) activity, an enzyme marker of
mitochondrial mass, increase in progression from control endometrium to hyperplasia to type I endometrial
carcinoma.
Results: Given that no statistically significant change in mtDNA content and CS activity in endometrium taken from
different phases of the menstrual cycle or in menopause was found, these samples were used as control. Our
research shows, for the first time, that mtDNA content and citrate synthase activity increase in hyperplastic
endometrium compared to control tissues, even if their levels remain lower compared to cancer tissue. In particular,
mtDNA content increases seem to precede increases in CS activity. No statistically significant change in mtDNA
content and in CS activity was found in relation to different histopathological conditions such as grade, myometrial
invasion and stage.
Conclusion: MtDNA content and citrate synthase activity increases in pre-malignant lesions could be a potential
molecular marker for progression from hyperplasia to carcinoma.
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The most common malignancy in the female genital
tract, endometrial carcinoma is classified in two main
types: estrogen-related (type I, endometrioid) and
non–estrogen-related (type II, nonendometrioid) [1].
Type II tumors behave aggressively and lack the proges-
terone responsiveness of type I tumors. The develop-
ment of endometrioid cancer is usually considered a
multistep process with slow progression from normal
endometrium to hyperplasia to cancer as a result of
excesses in endogenous or exogenous estrogens and/or
relative progesterone deficiency [2].* Correspondence: a.cormio@biologia.uniba.it
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reproduction in any medium, provided the orEndometrial hyperplasia is a pathologic condition
characterized by proliferation of endometrial glands with
a greater than normal gland-to-stroma ratio. About 1.6%
of patients diagnosed with these abnormalities can de-
velop endometrial cancer. Endometrial hyperplasia may
also be associated with cytologic atypia (atypical hyper-
plasia). While these features are similar to those seen in
true cancer cells, atypical hyperplasia does not show in-
vasion into the connective tissues, the defining charac-
teristic of cancer [3]. About 22% of patients with atypical
hyperplasia can develop cancer [4].
Mitochondria, which are essential organelles that gen-
erate cellular energy (ATP) through oxidative phosphor-
ylation, have long been suspected to play an important
role in the development and progression of cancer. War-
burg has hypothesized that a key event in carcinogenesis
is the development of an ‘injury’ to the respiratoryLtd This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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glycolytic ATP production [5]. The respiratory machin-
ery is the product of two genomes, nuclear genome and
mitochondrial genome. Mitochondrial DNA (mtDNA) is
a circular double-stranded molecule of 16569 bp that
codes for two rRNAs, 22 tRNAs and only 13 of about
100 proteins in the mitochondrial respiratory chain
complexes [6].
Recently, changes in mtDNA content have been inves-
tigated in solid tumors. A depletion of mtDNA induces
cancer progression in prostate, ovarian and breast cancer
[7-9]. Several studies have revealed an increased mtDNA
content in prostate [10], endometrial [11], and pancre-
atic cancer [12] as well as in thyroid and renal oncocy-
toma [13,14].
An increase in mtDNA content and citrate synthase
(CS) activity [15], an enzyme marker of mitochondrial
mass [16], has been reported in type I endometrial
cancer compared to proliferative endometrial control
tissues, suggesting an increase in mitochondrial biogen-
esis. A statistically significant increase in TFAM, NRF-1
and PGC-1α protein content, key factors in the PGC-1α
dependent mitochondrial biogenesis signalling pathway,
was found, moreover, in endometrial cancer tissue com-
pared to controls. This suggests that the increased mito-
chondrial biogenesis in type I endometrial cancer can be
associated with upregulation of PGC-1α signalling path-
way [15]. MtDNA mutations, associated with increases
in mitochondrial biogenesis, which result in the disas-
sembly of respiratory chain complexes, were noted in
type I endometrial cancer tissues for the first time.
MtDNA mutations did not occur in typical hyperplastic
or atrophic tissue surrounding tumour in the same
patient [17].
Since hyperplasia often precedes type I endometrial
carcinoma, it is vital to establish if increases in mtDNA
and/or CS activity appear early in hyperplastic endomet-
rium and if these changes can be considered possible
markers for progression from benign to premalignant
lesions. For this reason mtDNA content and CS activity
were measured in endometrial tissue taken from differ-
ent phases of the menstrual cycle (proliferative,
secretory) or in menopause (atrophic), in hyperplastic
(atypical or typical) and cancer tissue.
Results
Analysis of mtDNA content in control, hyperplastic and
cancer endometrial tissues
MtDNA content relative to nuclear DNA content
(mtDNA/nDNA) in 16 proliferative, 7 secretive and 9
atrophic endometria was measured by real-time PCR.
No statistically significant difference was found in the
mean value of mtDNA/nDNA ratio between proliferative
(mean ± SD= 286 ± 96), secretive (mean ± SD= 316 ± 98)and atrophic endometria (mean ± SD= 323 ± 206). These
three types of endometrium were therefore considered
all together and the mean value of their mtDNA/nDNA
ratios was used as the control value.
The mtDNA/nDNA ratio was measured in 20 typical
and atypical hyperplastic tissues and in 40 samples of
type I endometrial adenocarcinoma. Figure 1A shows a
statistically significant increase in 1.4, 1.8 and 2-fold of
mtDNA content respectively in typical hyperplasia, atypical
hyperplasia and cancer compared to control. Compared to
cancer tissue mtDNA content is lower in typical and
atypical hyperplastic samples, but only statistically signifi-
cant for typical hyperplasia.
Citrate synthase activity in control, hyperplastic and
cancer endometrial tissues
To verify if increases in mtDNA content are associated
with increases in mitochondrial mass, CS activity was
measured in the homogenate of 16 endometrial control
samples (8 proliferative and 6 atrophic endometria), 9
hyperplastic samples that were divided into typical and
atypical hyperplasia, and 12 endometrial cancer samples.
No statistically significant difference was found in the
mean value of CS activity between proliferative (mean ±
SD= 2.16 ± 0.79) and atrophic endometria (mean ± SD =
1.96 ± 0.42). These two types of endometrium were
therefore considered all together and the mean value of
their CS activity was used as the control value. Figure 1B
shows that there is a statistically significant 2 and 3- fold
increase in CS activity compared to the control tissues
in atypical hyperplasia and in cancer tissue respectively.
In typical and atypical hyperplasia, however, CS activity
is significantly lower compared to cancer tissue samples.
MtDNA content and citrate synthase activity in cancer
progression
MtDNA content and CS activity in cancer tissue samples
were analyzed in relation to different histopathological
conditions such as grade, myometrial invasion and stage.
No statistically significant change in mtDNA content
and CS activity was found in cancer progression (data
not shown). At the more advanced stage (stage IV), and
with highest grade (G3) tumours, however, mtDNA con-
tent seemed to decrease compared to stage 1 and grade
1 tumors (respectively for stage 486±56 vs 645±31 and
for grade 503± 71 vs 689±67). No evaluation of CS activ-
ity was possible in relation to cancer stage due to limited
availability of tissue samples.
Discussion
Diagnosis of premalignant lesions in routine endometrial
biopsies has great clinical value in patient management.
A number of possible molecular markers (PTEN, Bcl-2,













































































Figure 1 A) MtDNA content in control, typical hyperplasia, atypical hyperplasia and cancer. MtDNA content has been measured as
mtDNA/nDNA ratio. Bars represent the average ± standard deviation of values obtained from different samples analysed in triplicate in 3–4
experiments. n, number of analysed samples. B) Citrate synthase activity in control, typical hyperplasia, atypical hyperplasia and cancer.
Measurements of citrate synthase activity (μmoli x min-1x g tissue-1) were performed in cellular homogenate. Bars represent the
average± standard deviation of values obtained from different samples analysed in triplicate in 3 different experiments. *p< 0.05 and **p< 0.001
statistically significant differences versus control. } p< 0.05 statistically significant difference versus cancer.
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there is no reported data concerning mtDNA content and
CS activity in hyperplastic tissue and endometrial carcino-
genesis, we have tried to establish if changes in mtDNA
content and/or CS activity could be potential molecular
markers of progression from hyperplasia to carcinoma. To
this end mtDNA content and CS activity were measured in
normal endometrium from different phases of the men-
strual cycle, in hyperplasia and cancer. MtDNA was
expressed as a mtDNA/nuclearDNA ratio. MtDNA, in fact,
replicates independently from nDNA so that copies of
mtDNA per cell can change under different cell conditions[6]. Since changes in the ploidy have rarely been reported
in hyperplasia and type I endometrial cancer [20], the
mtDNA/nDNA ratio could indicate increases or decreases
in mtDNA copy number per single cell.
Our research shows that mtDNA content and CS
activity increase in progression from benign endomet-
rium to hyperplasia and to carcinoma. MtDNA content
increases precede increases in CS activity. While
mtDNA could therefore be considered as one of the fac-
tors that begin to increase early in typical hyperplasia, it
is more evident in atypical hyperplasia where malignant
transformation is more probable. CS activity was found
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control tissues. This increase could be the result of
mitochondrial proliferation that probably begins with an
increase in mtDNA content in typical hyperplasia.
In recent years there has been increasing evidence
pointing to the mitochondrial respiratory chain (MRC)
as a novel and important target for the action of estro-
gen and estrogen receptors (ER). ER is also localised in
mitochondria while E2 up-regulates transcript levels of
several mtDNA and nuclear genes encoding MRC pro-
teins [21]. Estradiol has been reported to increase
mtDNA content in breast and lung adenocarcinoma
cells that directly stimulate NRF-1 gene expression and
increase TFAM expression, mitochondrial transcription
and oxygen consumption [22]. In human breast cancer
cells, on the other hand, estradiol produces high rates of
mitochondrial reactive oxygen species (ROS) that act as
signal transducing factors activating NRF-1 [23]. Inter-
estingly, enhanced lipid peroxidation and altered antioxi-
dant enzyme activities were found in patients with
endometrial hyperplasia and cancer compared to
patients with benign disease [17,24]. Moderate increases
in mitochondrial biogenesis reported here in endomet-
rial hyperplasia could be either as a direct result of
estrogen or a cellular attempt to counteract estrogen
ROS increase. In our previous work we have found patho-
genetic mtDNA mutations in type I endometrial cancer
tissue associated with more evident increases in mito-
chondrial biogenesis compared to typical hyperplastic or
atrophic tissue surrounding tumours and the activation of
oxidative stress response mechanisms [17]. In cancer
tissue induction of mitochondrial biogenesis might also
be explained as a compensatory response to pathogenic
mtDNA mutations.
No statistically significant differences in mtDNA
content and CS activity were found in tumour samples
classified according to known prognostic factors (grade,
depth of myometrial invasion and stage). A slight
decrease in mtDNA content, while not statistically
significant, seemed, however, to be present in high grade
tumours. This trend can be explained by the fact that
high grade tumours are less exposed to estrogen and are
characterised by a high rate of cell division which could
in turn be responsible for the lower number of mito-
chondria per cell.
Conclusions
We note here for the first time moderate increases in
mitochondrial biogenesis in hyperplastic tissues probably
linked to estrogen stimulation. Of the two types of
hyperplasia atypical hyperplasia seems to be more
affected by this stimulation than typical hyperplasia. A
more significant increase in mitochondrial biogenesis is
found in cancer tissue probably as a compensatoryresponse to damage caused by mtDNA mutations.
MtDNA mutations would seem therefore to enhance
estrogen stimulation as a synergic mechanism.
Different levels in mtDNA and CS activity, therefore,
could be used as possible molecular markers to establish
the risk of malignant transformation in endometrial
hyperplasia.
Methods
This study was carried out using endometrial tissue
samples obtained from patients who underwent laparo-
tomic hysterectomy between January 2007 and June
2008 at the Department of Gynecology, Obstetrics and
Neonatology, University of Bari, Italy. Following surgery,
tissues were snap-frozen in liquid nitrogen and stored at
−80°C. None of the patients had received any treatment
(radiotherapy, chemotherapy or hormone therapy)
before surgery. Endometrial tissue samples were ana-
lysed from patients in different phases of the menstrual
cycle (16 proliferative and 7 secretive) or in menopause
(9 atrophic) who underwent hysterectomy for benign
conditions such as uterine prolapse and ovarian cysts.
The mean age of these patients is 51 ± 9 years (range
37 to 78). Endometrial hyperplasia samples (5 atypical,
15 typical) were taken from 6 patients who underwent
hysterectomy for hyperplasia diagnosis and from 14
patients affected by hyperplasia and type I endometrial
carcinoma. The mean age of these patients is
65 ± 13 years (range 46 to 86). All endometrial samples
were characterised histologically. Neoplastic endomet-
rial tissue samples were analysed from 40 patients
affected by type I endometrial carcinoma. The mean
age of these patients is 69 ± 12 years (range 46 to 86).
Stage, miometrial invasion and grading of endometrial
carcinoma were assigned according to categories
devised by the International Federation of Gynecology
and Obstetrics (FIGO), 2007 and 2008 [25]. All clinical
samples were collected under protocols approved by
Institutional Review Board of the University Hospital
of Bari, Italy.
Total DNA was prepared from endometrial tissue
using NucleoSpin Tissue Kit (Machinary-Nagel) and
stored at −20°C. MtDNA content was measured by
real-time PCR using an ABI Prism 7000 real-time PCR
(Applied Biosystems). As previously reported [15],
mtDNA content was related to nuclear DNA (nDNA)
amount. The difference in threshold cycle values of
nuclear Beta Actin gene and mitochondrial ND1 gene
(ΔCt, namely CtND1–CtActin) was used as a measure for
the relative abundance of the mitochondrial genome.
The mtDNA/nDNA ratio is reported as 2-ΔCt.
Total proteins were extracted from 20 mg of frozen
endometrial samples. Citrate synthase activity (μmol x
min–1 x g tissue–1) was measured according to [15]
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ANOVA test or t-student’s test was used. Statistical signifi-
cance was set at p< 0.05.
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